<DOC>
	<DOCNO>NCT00607152</DOCNO>
	<brief_summary>Primary : To compare efficacy Rasburicase versus allopurinol control tumor lysis-related hyperuricemia Chinese patient leukemia lymphoma . Secondary : To compare efficacy safety Rasburicase versus allopurinol Chinese patient stratify accord disease ( leukemia lymphoma ) .</brief_summary>
	<brief_title>Rasburicase ( Fasturtec ) Registration Trial</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>At high risk malignancy and/or chemotherapyinduced hyperuricemia Performance status le 3 ECOG scale 30 % KPS scale Uric acid concentration â‰¥ 8.0mg/dL Suffering nonHodgkin 's lymphoma Stage III , acute lymphoblastic leukemia peripheral blood cell count 25,000/mm3 , lymphoma leukemia Treatment investigational drug time 14day study period ( except agent permit Sponsor ) Pregnancy lactation Prior treatment Uricozyme Rasburicase Scheduled receive asparaginase either 24 hour first dose rasburicase Treatment Allopurinol within seven day precede study Day 1 History significant atopic allergy problem document history asthma History severe reaction allopurinol Known history glucose6phosphate dehydrogenase deficiency . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>